CollPlant Biotechnologies (CLGN) Q2 2026 earnings summary

Executive summary

• September acquisition of LightSolver expanded operations into photonic computing alongside regenerative medicine; June 30 financial results exclude LightSolver.

• Regenerative medicine strategy remains focused on rhCollagen applications in medical aesthetics and 3D bioprinting, with strategic collaborations and commercialization as priorities.

Financial highlights

• Q2 2026 revenue was $108K vs. $179K YoY; H1 revenue was $181K vs. $2.234M, including a non-recurring $2.0M milestone recognized in H1 2025.

• Q2 gross loss was $456K vs. $7K; H1 gross loss was $699K vs. $1.860M gross profit, reflecting higher costs and lower facility utilization.

• Q2 GAAP operating expenses fell to $2.2M from $3.2M; H1 fell to $5.0M from $6.7M, primarily from cost reductions.

• Q2 GAAP net loss narrowed to $2.7M from $3.3M; H1 GAAP net loss widened to $5.8M from $4.8M.

• H1 non-GAAP net loss was $5.4M vs. $3.9M; non-GAAP excludes share-based compensation and changes in operating lease accounts.

Outlook and guidance

• Losses and negative operating cash flows are expected to continue until products reach commercial profitability; current resources are insufficient to fund operations for the next 12 months.

• Planned funding sources include LightSolver commercialization, rhCollagen licensing and collaborations, additional equity or debt financing, and expense adjustments.

• LightSolver remains in development; priorities include validating, scaling and commercializing its LPU technology while pursuing rhCollagen partnerships and out-licensing.